Previous 10 | Next 10 |
BOTHELL, Wash., May 04, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces that new data from its CC-42344 Phase 1 influenza A Study was presented today by Sam Lee, Ph.D., President and co-CEO, at the 7 th Annual International Society for I...
BOTHELL, Wash., April 24, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces the appointment of Fred Hassan to its Board of Directors, increasing its Board membership to six. Mr. Hassan’s distinguished 40-year career includes serving in se...
BOTHELL, Wash., April 18, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces the acceptance of an oral presentation containing new data from the Company’s CC-42344 Phase 1 influenza A study at the 7 th Annual International Society fo...
2023-04-10 10:28:20 ET Penny stocks are low-priced shares of companies that are generally smaller organizations. Though there can be exceptions to the rule, retail traders tend to lean toward these types of companies because of a history of significant potential. There aren’t many pl...
2023-04-10 09:03:30 ET Cocrystal Pharma ( NASDAQ: COCP ) has announced the completion of a private placement of 2.03M shares of common stock at a price of $1.97/share for proceeds of $4M . Through this private placement Dr. Frost has increased his holdings and we...
2023-04-10 08:55:07 ET OncoSec Medical ( ONCS ) +65%.GlucoTrack ( GCTK ) +29%.Guardforce AI ( GFAI ) +22%.Eloxx Pharmaceuticals ( ELOX ) +15%.Cocrystal Pharma ( COCP ) +13% on completing $4 Million private placement priced at-the-market under Nasdaq rules.Enlivex Therape...
BOTHELL, Wash., April 10, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces the completion of a private placement of 2,030,458 shares of common stock at a price of $1.97 per share for proceeds of $4.0 million. Investors in the private placement ...
2023-03-29 08:28:15 ET Cocrystal Pharma press release ( NASDAQ: COCP ): FY GAAP EPS of -$4.77. Cocrystal reported unrestricted cash of $37.1 million as of December 31, 2022 Net cash used in operating activities for 2022 was $21.4 million. The Company reported...
BOTHELL, Wash., March 29, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) reports financial results for the 12 months ended December 31, 2022, and provides updates on its antiviral pipeline, upcoming milestones and business activities. “This is an eventful time for C...
BOTHELL, Wash., March 22, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, CFO and co-CEO, will present a company overview at the Virtual Investor Summit Conference being held on Wednesday, March 29, 2023 at 10:30 a.m. Eastern time. “This ...
News, Short Squeeze, Breakout and More Instantly...
Cocrystal Pharma Inc. Company Name:
COCP Stock Symbol:
NASDAQ Market:
Cocrystal Pharma Inc. Website:
BOTHELL, Wash., June 20, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc .’s (Nasdaq: COCP) novel, broad-spectrum antiviral CC-42344 inhibits activity in the highly pathogenic avian influenza A (H5N1) PB2 protein recently identified in infected dairy cattle, according to recently ...
Topline single ascending dose (SAD) Phase 1 results of oral CDI-988, the first potential pan-coronavirus-pan-norovirus oral antiviral, expected in the second quarter of 2024 Enrollment completed in Phase 2a influenza A human challenge study of oral CC-42344, with topline results expected ...
BOTHELL, Wash., May 01, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces completion of enrollment of 78 subjects who were infected with influenza A in a randomized, double-blind, placebo-controlled Phase 2a human...